The association between Caveolin-1 expressions with clinicopathological characteristic of breast cancer

Pande Made Krisna Ekassiana, I Gede Putu Supadmanaba, Desak Made Wihandani, Putu Anda Tusta Adiputra

Pande Made Krisna Ekassiana
Department of Surgery, Faculty of Medicine Universitas Udayana, Bali, Indonesia

I Gede Putu Supadmanaba
Biochemistry Department Faculty of Medicine Universitas Udayana, Bali, Indonesia

Desak Made Wihandani
Biochemistry Department Faculty of Medicine Universitas Udayana, Bali, Indonesia

Putu Anda Tusta Adiputra
Oncologic Surgery Subdivision, Department of Surgery, Faculty of Medicine Universitas Udayana, Bali, Indonesia. Email: andatusta@yahoo.co.id
Online First: December 01, 2019 | Cite this Article
Ekassiana, P., Supadmanaba, I., Wihandani, D., Adiputra, P. 2019. The association between Caveolin-1 expressions with clinicopathological characteristic of breast cancer. Bali Medical Journal 8(3): S774-S779. DOI:10.15562/bmj.v8i3.1587

Introduction: Currently, prognostic determination of breast cancer often posed a challenge to oncologists due to variability in many molecular processes and metabolism. Caveolin-1 is caveolae protein that is closely related to tumour metabolism and had been proved to be associated with the level of malignancy in pre-clinical studies, but there is still no clinical evidence about Cavolin-1. Therefore, this study aimed to evaluate the association between the expressions of Caveolin-1 with clinicopathological characteristics of breast cancer.

Methods: An analytical cross-sectional study was conducted in Sanglah General Hospital and Biochemistry Laboratory by using 78 subjects. The clinicopathological characteristics were recorded from medical records while Caveolin-1 expression was determined by IHC.

Results: Caveolin-1 expression was found to be significantly associated with clinical stadium, subtype, histological grade and LVI in bivariate analysis. Multivariate analysis found significant only in three of them with high expression of Caveolin-1 was associated with early stadium, negative LVI and Luminal A subtype.

Conclusion: Caveolin-1 expression is significantly associated with clinical stadium, LVI and subtype in breast cancer with high expression often delineate early stage, negative LVI and luminal A subtype.


World Health Organization.2014. World Cancer Report. IARC 2015

World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Breast Cancer.

Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet. 2014;6736(14):61396-9.

Cancer Research UK. Breast Cancer Statistics. CRUK. 2015 Accessed: 2 Mei 2015

Krigjsman O, Roepman P, Zwart W, et.al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2011; 1007:10549-11

Badve S, Dabbs DJ, Schnitt SJ, et.al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology. 2011;24:157–167

Bombonati A, Sgroi DC. The Molecular Pathology of Breast Cancer Progression. J Pathol. 2011; 223(2): 307–317

Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL. A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J BioenergBiomembr. 2012;44(1):163-70

Gonzales CD, Alvarez S, Ropolo A, et al. Autophagy, Warburg, and Warburg Reverse Effects in Human Cancer. BioMed Research International. 2014; 12:1-10

Wietkiwicz AK, Menezes DW, Dasgupta A, et al. Stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 2012;11(6), 1108-1117

Sotgia F, Martinez-Ooutschoorn UE, Pavlides S, et.al. Understanding theWarburg effect and the prognostic value of stromal Caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Research. 2011;13(213):1-13

Hehlgans S, Cordes N. et al. Caveolin-1: An essential modulator of cancer cell ratio and chemoresistance. American Journal of Cancer Research. 2012;1(4):521-530

Liu P, Rudicks M, Anderson RG. Multiple Functions of Caveolin-1. The Journal of Biological Chemistry. 2002:277(44);41295-8

Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, et.al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle. 2010;15;9(10):1960-71

Radisky ES, Radisky DC. Matrix Metalloproteinase-Induced Epithelial-Mesenchymal Transition in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia. 2010;15(2):201-212.

Seyfried TN, Huysentruyt LC. On the Origin of Cancer Metastasis. Critical reviews in oncogenesis. 2013;18(1-2):43-73

Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World Journal of Clinical Oncology. 2014;5(3):283-298.

Viale G. The current state of breast cancer classification. Ann Oncol. 2012.;23 Suppl 10:x207-10.

Prabawa I, Bharghah A, Liwang F, Tandio D, Tandio A, Lestari A, Budiana I, Manuaba I. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pacific Journal of Cancer Prevention. 2019;20(3):863-868. doi: 10.31557/APJCP.2019.20.3.863

No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0